Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy

Next Previous
X
Search
Trial Profile

QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Molecularly Informed Integrated Immunotherapy Combining (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With SCC Who Have Progressed on or After Platinum-based Chemotherapy and Anti-programmed Cell Death Protein 1 (PD-1)/Programmed Death-ligand 1 (PD-L1) Therapy

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aldoxorubicin (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Brachyury peptide vaccine (Primary) ; Capecitabine (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX 021 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; GI 4000 (Primary) ; GI 6207 (Primary) ; High affinity CD-expressing natural killer cell therapy ImmunityBio (Primary) ; Necitumumab (Primary) ; Nogapendekin alfa inbakicept (Primary) ; Omega-3-acid ethyl esters (Primary) ; Paclitaxel (Primary)
  • Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms QUILT-3.090
  • Sponsors ImmunityBio; NantKwest

    • Most Recent Events

    • 05 Aug 2024 Status changed from active, no longer recruiting to discontinued, study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.
    • 10 Aug 2020 Planned End Date changed from 1 Dec 2019 to 1 Apr 2021.
    • 10 Aug 2020 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top